Table 2 Patient characteristics at 10 months after onset of STEMI according to chronic-phase plasma TMAO levels.
From: Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI
All patients N = 112 | TMAO levels in the chronic phase | P | ||
|---|---|---|---|---|
Below median n = 56 | Above median n = 56 | |||
Age, years | 64 (57–72) | 62 (53–69) | 66 (59–73) | 0.062 |
Male sex, n (%) | 99 (88%) | 54 (96%) | 45 (80%) | 0.016 |
Body weight, kg | 65.3 (58.5–73.8) | 68.1 (60.0–77.0) | 62.5 (53.6–71.1) | 0.016 |
Body mass index, kg/m2 | 24.1 (22.0–26.6) | 24.6 (22.5–26.1) | 23.4 (20.5–25.5) | 0.033 |
Systolic blood pressure, mmHg | 117 (108–132) | 116 (108–130) | 118 (110–134) | 0.50 |
Diastolic blood pressure, mmHg | 70 (61–80) | 70 (62–82) | 68 (60–78) | 0.49 |
Coronary risk factors | ||||
Hypertension, n (%) | 54 (48%) | 26 (46%) | 28 (50%) | 0.85 |
Dyslipidemia, n (%) | 69 (62%) | 34 (62%) | 35 (63%) | >0.99 |
Diabetes, n (%) | 32 (29%) | 17 (30%) | 15 (27%) | 0.83 |
Smoking, n (%) | 83 (74%) | 40 (71%) | 43 (77%) | 0.67 |
Laboratory data after 10 months | ||||
Total cholesterol, mg/dl | 153 (138–167) | 153 (137–174) | 153 (139–161) | 0.50 |
HDL cholesterol, mg/dl | 46 (39–55) | 44 (40–53) | 46 (37–59) | 0.72 |
LDL cholesterol, mg/dl | 81 (70–96) | 85 (76–100) | 79 (69–92) | 0.042 |
Triglycerides, mg/dl | 133 (97–204) | 132 (99–213) | 138 (83–199) | 0.59 |
Glucose, mg/dl | 118 (100–146) | 117 (100–135) | 124 (101–157) | 0.26 |
HbA1c, % | 6.0 (5.8–6.6) | 6.0 (5.8–6.7) | 6.1 (5.8–6.5) | 0.71 |
eGFR, ml/min/1.73 m2 | 69 (56–78) | 70 (59–80) | 66 (56–75) | 0.116 |
BNP, pg/ml | 38 (15–57) | 32 (15–57) | 44 (17–60) | 0.29 |
CRP, mg/L | 0.69 (0.36–1.54) | 0.66 (0.37–1.63) | 0.75 (0.35–1.47) | 0.79 |
Anterior wall MI, n (%) | 55 (49%) | 29 (52%) | 26 (46%) | 0.71 |
Peak CK-MB, IU/L | 195 (94–319) | 204 (89–324) | 178 (96–284) | 0.69 |
SYNTAX score 10 months later | 11 (7–18) | 10 (6–15) | 11 (7–19) | 0.11 |
TMAO levels in the acute phase, μM | 5.63 (3.20–10.38) | 5.21 (2.89–9.39) | 5.89 (3.45–12.80) | 0.53 |
Medications after 10 months | ||||
Aspirin, n (%) | 112 (100%) | 56 (100%) | 56 (100%) | >0.99 |
P2Y12 inhibitors, n (%) | 109 (97%) | 53 (95%) | 56 (100%) | 0.24 |
Clopidogrel, n (%) | 64 (57%) | 30 (54%) | 33 (59%) | |
Ticlopidine, n (%) | 43 (38%) | 22 (39%) | 21 (38%) | |
Prasugrel, n (%) | 1 (1%) | 0 (0%) | 1 (2%) | |
Beta blocker, n (%) | 96 (86%) | 51 (91%) | 45 (80%) | 0.18 |
ACE-I/ARB, n (%) | 107 (96%) | 51 (91%) | 56 (100%) | 0.057 |
Statin, n (%) | 110 (98%) | 56 (100%) | 54 (96%) | 0.50 |
